Related Experiment Video
Updated: Mar 29, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
New therapeutic agents for acromegaly
1Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA.
New therapies for acromegaly, including oral octreotide and investigational agents like DG3173, offer improved treatment options. These treatments aim to safely control growth hormone (GH) and insulin-like growth factor 1 (IGF-1) with better efficacy and fewer side effects.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology and Therapeutics
Background:
- Current somatostatin receptor ligands (SRLs) and GH antagonists for acromegaly have limitations including variable efficacy, adverse effects, and frequent injections.
- Acromegaly management requires effective and well-tolerated therapies to control GH and IGF-1 levels and alleviate symptoms.
Purpose of the Study:
- To review the need for novel therapeutic agents in acromegaly treatment.
- To summarize clinical trial data for investigational acromegaly therapies.
- To discuss the potential integration of new treatments into clinical practice.
Main Methods:
- Review of clinical trial data for oral octreotide capsules, DG3173, CAM2029, and GH receptor antisense oligonucleotides.
- Analysis of safety and efficacy profiles of current and investigational acromegaly treatments.
- Discussion of therapeutic strategies and clinical integration.
Main Results:
- Oral octreotide capsules demonstrated safe and sustained suppression of GH and IGF-1 in acromegaly patients, reducing symptoms without injection-site reactions.
- Investigational agents (DG3173, CAM2029, GH receptor antisense oligonucleotide) show promise for biochemical suppression with favorable safety profiles.
- Emerging therapies offer potential for improved acromegaly management compared to existing treatments.
Conclusions:
- New therapeutic agents are needed to address the limitations of current acromegaly treatments.
- Investigational therapies show promise for effective and safer management of acromegaly.
- Successful integration of these novel agents into clinical practice could significantly improve patient outcomes.
More Related Videos
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
10:36In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...